Literature DB >> 9918588

Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.

T Kuroki1, H Y Meltzer, J Ichikawa.   

Abstract

The present study was designed to compare the effects of typical and atypical antipsychotic drugs on extracellular dopamine (DA) levels in the medial prefrontal cortex (mPFC) and the nucleus accumbens (NAC), using in vivo microdialysis with dual probe implantation in awake, freely moving rats. Amperozide (2 and 10 mg/kg), clozapine (5 and 20 mg/kg), and olanzapine (10 mg/kg), all of which are atypical antipsychotics, produced greater increases in extracellular DA levels in the mPFC than in the NAC. Olanzapine (1 mg/kg), risperidone (0.1 and 1 mg/kg), also an atypical antipsychotic, and S-(-)-sulpiride (25 mg/kg), a typical antipsychotic, produced comparable increases in extracellular DA levels in the mPFC and the NAC. S-(-)-sulpiride (10 mg/kg) and haloperidol (0.1 and 1 mg/kg), another typical antipsychotic, significantly increased extracellular DA levels in the NAC but not in the mPFC. The effects of the six antipsychotic drugs to increase extracellular DA levels in the mPFC relative to those in the NAC was positively correlated with the difference between their pKi values for serotonin (5-hydroxytryptamine, 5-HT2A) and DA-D2 receptors and was inversely correlated to their pKi values for D2 or D3 receptors, but was not for 5-HT2A receptors alone. These results are consistent with the hypothesis that the ability of antipsychotic drugs to produce a greater increase in prefrontal compared with NAC extracellular DA levels may be related, in part, to weak D2 and D3 receptor affinity relative to 5-HT2A receptor antagonism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918588

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  68 in total

1.  Cognition, schizophrenia, and the atypical antipsychotic drugs.

Authors:  H Y Meltzer; S Park; R Kessler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  The physiological role of 5-HT2A receptors in working memory.

Authors:  Graham V Williams; Srinivas G Rao; Patricia S Goldman-Rakic
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

3.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.

Authors:  Philip D Harvey; Michael F Green; Susan R McGurk; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

4.  Risperidone diminishes cocaine-induced craving.

Authors:  Richard De La Garza; Thomas F Newton; Ari D Kalechstein
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

Review 5.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 6.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.

Authors:  Y Chertkow; O Weinreb; M B H Youdim; H Silver
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

Review 8.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Authors:  Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

10.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.